Imagion to Present Prostate Cancer Research Data at WMIC 2022

Imagion to present prostate cancer research data at World Molecular Imaging Congress MagSense® molecular imaging agent shows high specificity and selectivity……


Iron Oxide Nanoparticles in Lipid Delivery System May Lead to Better Cancer Treatment

Lipids are frequently used to form drug carrying nanoparticles because of their favorable biocompatibility. However, construction of such drug-carrying lipid…


Imagion Biosystems Nanoparticles Used in Viral Therapy Research

Imagion Biosystems Limited is pleased to share news of a recent publication, led by researchers at the Weill Cornell Medical College, which reports use of the…


2019 World Molecular Imaging Conference Poster

This study is the Company's first reported results demonstrating that the anti-HER2 nanoparticles used in Imagion's Magsense™ technology, which provide…


HER2 Nanoparticle Safety and Specificity Data Presented at AACR 2019

Marie Zhang, PhD, Vice President of Research and Clinical Development at Imagion Biosystems, presented the poster "HER2 Functionalized Nanoparticles Are Safe…


MagSense® Pre-Clinical Study Presented at 2018 SABCS

On Saturday, December 8, 2018, Marie Zhang, PhD presented the poster "Detection of HER2 Positive Tumor Cells Using Functionalized Iron Oxide Nanoparticles" at…


MagSense® Technology at ASCO 2018 Annual Meeting

The ASCO 2018 Annual Meeting abstract, "Detection and measurement of HER2+ breast cancer cells using tumor-targeted iron oxide nanoparticles and magnetic…


MagSense® Pre-Clinical Safety Data from AACR 2018

Pre-clinical data on Imagion Biosystems' MagSense HER2+ cancer detection platform have shown: specific binding and detection of HER2+ tumor cells in vitro…